Notas de prensa

  • 4 de diciembre de 2006
  • 11
  • Sin apartado

Amgen Responds to Reports About Use and Safety of EPOGEN and Aranesp in CKD Anemia Therapy

THOUSAND OAKS, Calif., Dec 04, 2006 (BUSINESS WIRE) -- Amgen (NASDAQ:AMGN), today posted to its corporate web site documents intended to clarify Amgen´s position on the use of EPOGEN(R) (Epoetin alfa) and Aranesp(R) (darbepoetin alfa) and to correct what the company believes are misleading and inaccurate news reports regarding the use of its drugs. Amgen´s mission is to serve patients and the company is committed to ensuring the highest standards of patient safety.

Documents supporting the following statements have been posted on the company´s web site ( under the link Amgen Responds to Reports About the Use and Safety of its Products. The documents include: 1) Amgen´s Response to Reports about the Use and Safety of its Products in Anemia Therapy; 2) Amgen´s Response to the CHOIR and CREATE Clinical Trial Data; 3) Amgen´s Letter to Nephrologists and 4) an interview with the Center for Medicare & Medicaid Services (CMS) Chief Medical Officer Barry Straube that was initially published in Inside CMS.

-- EPOGEN and Aranesp are effective and safe medicines when administered according to the Food and Drug Administration (FDA) label.


Suscríbete para conocer las novedades del mundo farmacéutico y sanitario.

¿Qué es?

FarmaNews pone a disposición de los medios y departamentos de comunicación, un canal para publicar notas de prensa y convocatorias del mundo sanitario y farmacéutico.


C/ Pau Clarís, 21, local 2
08780, Pallejà, Barcelona